Seagen Phase 3 Trial Of TUKYSA In Combination With Antibody-Drug Conjugate Ado-Trastuzumab Emtansine Meets Primary Endpoint Of Progression-Free Survival In Patients With Previously Treated HER2-Positive Metastatic Breast Cancer
Portfolio Pulse from Happy Mohamed
Seagen Inc. (NASDAQ:SGEN) announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) met its primary endpoint of progression-free survival (PFS) in patients with previously treated HER2-positive metastatic breast cancer. The company plans to present the data at an upcoming medical meeting and discuss the results with the FDA.
August 16, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seagen's successful Phase 3 trial of TUKYSA could potentially lead to increased investor confidence and a positive impact on the company's stock.
The successful trial results indicate that Seagen's TUKYSA could become a viable treatment option for patients with previously treated HER2-positive metastatic breast cancer. This could potentially lead to increased sales and revenue for the company, which would likely be viewed positively by investors and could result in an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100